目的 了解天津市津南區(qū)咸水沽醫(yī)院降糖類藥物的使用情況和變化趨勢，為促使臨床合理應(yīng)用提供參考。方法 采用回顧性分析方法，對(duì)2015-2017年天津市津南區(qū)咸水沽醫(yī)院門診降糖類藥物的銷售金額、使用頻度（DDDs）、日均費(fèi)用（DDC）和排序比（B/A）等進(jìn)行統(tǒng)計(jì)并排序、分析。結(jié)果 注射類和口服類降糖藥物的銷售金額和DDDs均呈先上升后下降的趨勢。注射類降糖藥的銷售金額、DDDs都穩(wěn)居第1位。口服類降糖藥中，α-葡萄糖苷酶抑制劑的銷售金額、DDDs都高居榜首，其次是非磺酰脲類促泌劑。阿卡波糖片的銷售金額、DDDs排序始終居首位，其次是瑞格列奈片，銷售金額居第2位。胰島素類各品種的金額和DDDs排序無明顯浮動(dòng)，排名基本穩(wěn)定。其中長效胰島素類似物的銷售金額排名逐年上升，2017年排名躍居第1位，預(yù)混胰島素類似物的DDDs排名始終居首位。注射類和口服類降糖藥的B/A比值均接近1.00，說明患者同步性良好。結(jié)論 天津市津南區(qū)咸水沽醫(yī)院降糖類藥物使用基本合理，個(gè)別藥物如阿卡波糖片的使用量明顯超過指南中推薦的一線用藥二甲雙胍類。

Objective To understand the usage and changing trend of antidiabetic drugs in Jinnan Xianshuigu Hospital of Tianjin City, so as to provide basis for the rational application of antidiabetic drugs in clinic. Methods A retrospective analysis method was used to analyze the sales amount, frequency of use (DDDs), daily average cost (DDC), and B/A of Department of Outpatient of Tianjin Xianshuigu Hospital from 2015 to 2017. Results The sales volume and DDDs of injectable and oral antidiabetic drugs showed a trend of first increasing and then decreasing. Sales amount and DDDs of injectable antidiabetic drugs were ranked the first. Sales amount and DDDs of α-glucosidase inhibitor in oral antidiabetic drugs were ranked the top, followed by non-sulfonylurea secretagogues. Sales amount and DDDs of Acarbose Tablets were always ranked first, followed by Repaglinide Tablets in second place. The sequence of sales amount and DDDs of various types of insulin had no obvious floating, and the rankings were basically stable. Among them, the sales amount sequence of long-acting insulin analogs increased year by year, and sales amount of long-acting insulin analogs were ranked the first in 2017. DDDs of premixed insulin analogues were always ranked the first. The B/A ratio of injectable and oral antidiabetic drugs were close to 1.00, indicating that patients had good synchronization. Conclusion The use of antidiabetic drugs in Jinnan Xianshuigu Hospital of Tianjin City is basically rational. The use of Acarbose Tablets significantly exceeds the recommended first-line metformin in the guidelines.